News

The clinical trial was designed to compare a new solid oral dose formulation of LX4211 to the liquid dose formulation. The study results showed that 300mg solid oral

Under the agreement, Ziopharm will use Intrexon’s UltraVector Technology to develop and commercialize DNA-based therapeutics. Ziopharm will utilize Intrexon’s advanced transgene engineering platform to facilitate the controlled and

As per the terms of the agreement, Amgen has the option for the exclusive worldwide license of XmAb 5871 following the completion of a pre-defined Phase 2 study.

The joint venture CRO is based in Bangkok and is expected to conduct clinical research in key South East Asian countries under the name Ecron Acunova Company (EACL)

Skainar AL tablets contain azelastine hydrochloride as an active ingredient to inhibit the excessive production and release of histamine and leukotriene, two chemicals responsible for causing allergic symptoms.

The multi-dose, single-arm, multi-centre, open-label, dose-escalation Phase I study is designed to define the toxicity profile, maximum tolerated dose, immunogenicity, pharmacokinetics, and potential anti-tumour activity of MGAH22. The

As per the agreement, Spirogen will take the responsibility to manufacture and synthesize drug reagents to generate ADCs and investigate their potential therapeutic utility. Genentech will have the

Virdante has exclusively licensed the Sialic Switch technology from The Rockefeller University and established a strategic research alliance with Jeffrey Ravetch laboratory. The new US patent covers the

InSite Vision‘s Phase 1/2 study is designed to evaluate the safety and efficacy of ISV-303 when administered either once or twice daily. In the trial, the patients were